MedDataX Logo

The Effect of Tyrosine Kinase Receptor Axl on Dialysis Prognosis in Chronic Hemodialysis Patients

NCT ID: NCT04600219

Last Updated: 2020-11-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-01

Study Completion Date

2021-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate whether tyrosine kinase receptor Axl affects the dialysis prognosis in chronic hemodialysis patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is reported that hemodialysis (HD) patients often develop chronic systemic inflammatoion, and increased inflammatory activity is associated with vascular access failure, cardiovascular disease and death in HD patients. The interaction of Axl and its ligand Gas6 plays an important role in modulating immune response, inhabiting toll-like receptor (TLR) signaling and suppressing inflammatory cytokines production. Thus, we want to investigate the relationship between tyrosine kinase receptor Axl and the dialysis prognosis in HD patients in three-years follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemodialysis Complication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* hemodialysis for more than 6 months

Exclusion Criteria

* patients who received warfarin therapy;
* patients with chronic infectious disease or acute infection;
* patients with hemodialysis inadequacy;
* the age of patients is older than 65 years or younger than 18 years.
* patients who can not sign an informed consent or disagree to follow up
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ai Peng

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ai Peng

Director of the department of Nephrology,Shanghai 10th people's hospital

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ai Peng, MD,PhD

Role: STUDY_DIRECTOR

Shanghai 10th People's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital

Shanghai, Shanghai Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AHD2020

Identifier Type: -

Identifier Source: org_study_id